Literature DB >> 17704824

Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.

S E O'Sullivan1.   

Abstract

Cannabinoids act at two classical cannabinoid receptors (CB1 and CB2), a 7TM orphan receptor and the transmitter-gated channel transient receptor potential vanilloid type-1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator-activated receptors (PPARs, with three subtypes alpha, beta (delta) and gamma), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPAR alpha. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPAR alpha. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti-inflammatory properties mediated by PPAR alpha. Other endocannabinoids that activate PPAR alpha include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPAR gamma; anandamide and 2-arachidonoylglycerol have anti-inflammatory properties mediated by PPAR gamma. Similarly, ajulemic acid, a structural analogue of a metabolite of Delta(9)-tetrahydrocannabinol (THC), causes anti-inflammatory effects in vivo through PPAR gamma. THC also activates PPAR gamma, leading to a time-dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPAR gamma include N-arachidonoyl-dopamine, HU210, WIN55212-2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPAR delta. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro- and cardioprotective benefits as other PPAR alpha and PPAR gamma agonists? This review will summarize the published literature implicating cannabinoid-mediated PPAR effects and discuss the implications thereof.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704824      PMCID: PMC2190029          DOI: 10.1038/sj.bjp.0707423

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia.

Authors:  Isabel Matias; Marie-Paule Gonthier; Pierangelo Orlando; Vassilis Martiadis; Luciano De Petrocellis; Cristina Cervino; Stefania Petrosino; Laurence Hoareau; Franck Festy; Renato Pasquali; Regis Roche; Mario Maj; Uberto Pagotto; Palmiero Monteleone; Vincenzo Di Marzo
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

Review 2.  PPAR agonists in the treatment of atherosclerosis.

Authors:  Gordon A Francis; Jean-Sébastien Annicotte; Johan Auwerx
Journal:  Curr Opin Pharmacol       Date:  2003-04       Impact factor: 5.547

3.  Endocannabinoids in adipocytes during differentiation and their role in glucose uptake.

Authors:  V Gasperi; F Fezza; N Pasquariello; M Bari; S Oddi; A Finazzi Agrò; M Maccarrone
Journal:  Cell Mol Life Sci       Date:  2007-01       Impact factor: 9.261

4.  Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647.

Authors:  Roberto Russo; Jesse LoVerme; Giovanna La Rana; Giuseppe D'Agostino; Oscar Sasso; Antonio Calignano; Daniele Piomelli
Journal:  Eur J Pharmacol       Date:  2007-03-19       Impact factor: 4.432

5.  Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production.

Authors:  Jinah Hwang; Dean J Kleinhenz; Bernard Lassègue; Kathy K Griendling; Sergey Dikalov; C Michael Hart
Journal:  Am J Physiol Cell Physiol       Date:  2004-12-08       Impact factor: 4.249

6.  Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties.

Authors:  Giuseppe Astarita; Barbara Di Giacomo; Silvana Gaetani; Fariba Oveisi; Timothy R Compton; Silvia Rivara; Giorgio Tarzia; Marco Mor; Daniele Piomelli
Journal:  J Pharmacol Exp Ther       Date:  2006-05-15       Impact factor: 4.030

7.  Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.

Authors:  Mathieu Seimandi; Géraldine Lemaire; Arnaud Pillon; Agnès Perrin; Isabelle Carlavan; Johannes J Voegel; Françoise Vignon; Jean-Claude Nicolas; Patrick Balaguer
Journal:  Anal Biochem       Date:  2005-09-01       Impact factor: 3.365

8.  Cannabinoids and PPARalpha signalling.

Authors:  Y Sun; S P H Alexander; D A Kendall; A J Bennett
Journal:  Biochem Soc Trans       Date:  2006-12       Impact factor: 5.407

9.  Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line.

Authors:  Brad L Upham; Alisa M Rummel; Joseph M Carbone; James E Trosko; Yanli Ouyang; Robert B Crawford; Norbert E Kaminski
Journal:  Int J Cancer       Date:  2003-03-10       Impact factor: 7.396

Review 10.  Going nuclear in metabolic and cardiovascular disease.

Authors:  Christopher K Glass
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

View more
  183 in total

1.  Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

Authors:  Janis Noonan; Riffat Tanveer; Allan Klompas; Aoife Gowran; Joanne McKiernan; Veronica A Campbell
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase.

Authors:  Jay M West; Nikolai Zvonok; Kyle M Whitten; Jodianne T Wood; Alexandros Makriyannis
Journal:  J Proteome Res       Date:  2012-01-03       Impact factor: 4.466

Review 3.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

Review 4.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 5.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 6.  N-acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets.

Authors:  Mark Connor; Chris W Vaughan; Robert J Vandenberg
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 7.  The Endocannabinoid System and its Modulation by Phytocannabinoids.

Authors:  Vincenzo Di Marzo; Fabiana Piscitelli
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

8.  Endocannabinoid metabolism in neurodegenerative diseases.

Authors:  Chu Chen
Journal:  Neuroimmunol Neuroinflamm       Date:  2016-12-15

9.  Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.

Authors:  A A Martinez; M G Morgese; A Pisanu; T Macheda; M A Paquette; A Seillier; T Cassano; A R Carta; A Giuffrida
Journal:  Neurobiol Dis       Date:  2014-12-05       Impact factor: 5.996

Review 10.  Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder.

Authors:  Gaurav Bedse; Samuel W Centanni; Danny G Winder; Sachin Patel
Journal:  Alcohol Clin Exp Res       Date:  2019-08-21       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.